Newsroom

CSRxP Applauds FDA’s Biosimilars Action Plan

“We applaud Commissioner Gottlieb and the FDA for their leadership on increasing access to biosimilar medicines in the United States.  As the FDA noted, full access […]

Read more

CSRxP Releases Comments on Drug Price Blueprint

The Department of Health and Human Services is taking a good first step in the effort to reduce excessively high list prices, the Campaign for Sustainable […]

Read more

Statement on Celgene’s Revlimid Price Hike

CSRxP spokesman Will Holley released the following statement in response to today’s report that Celgene will once again raise the price of Revlimid: “Today’s announcement that […]

Read more

CSRxP Applauds Secretary Azar’s Focus on List Prices

CSRxP spokesman Will Holley released the following statement in response to Secretary Azar’s testimony in front of the Senate Finance Committee today: “The Administration’s focus on out-of-control […]

Read more